U.S. Markets open in 3 hrs 53 mins

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
1.60+0.02 (+1.27%)
At close: 4:00PM EDT
People also watch

Arrowhead Pharmaceuticals, Inc.

225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

Full Time Employees113

Key Executives

Dr. Christopher R. Anzalone Ph.D.CEO, Pres & Director1.06MN/A48
Mr. Kenneth A. Myszkowski MBA, CPAChief Financial Officer476.13k119.8k51
Dr. Bruce D. Given M.D.Chief Operating Officer694.03kN/A63
Mr. Patrick O'Brien J.D., PharmDGen. Counsel571.93kN/A53
Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate Governance

Arrowhead Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.